Hybrid Flagellin as a Novel T Cell Independent Vaccine Scaffold
- Technology Application
- This hybrid flagellin vaccine scaffold may be used to vaccinate individuals with less robust immune systems, including those in the early perinatal period, in people suffering from various T cell immunodeficiency disorders (HIV-AIDS, DiGeorge syndrome), patients undergoing chemotherapy, as well as elderly patients with sluggish adaptive immunity.
- Detailed Technology Description
- None
- Application No.
- 20180169205
- Others
-
Other Information
Related Publication:
Bennett, K. M. et al. Hybrid Flagellin as a T Cell Independent Vaccine Scaffold. BMC Biotechnol. 15, 71 (2015).
Images
Background
Vaccines are biological products that are able to establish resistance to specific antigens (diseases) in our bodies, through stimulating the immune system and creating antibodies. While traditional types of vaccines are based on weak live virus, killed virus or bacteria, newer versions are toxoid-based, or genetically engineered (including engineered microbes, subunit vaccines, conjugate vaccines, DNA vaccines, and vector vaccines). Vaccines have a total market size of around $32 billion (2016). This market is estimated to reach the level of nearly $48 billion by 2021, resulting in a compound annual growth rate (CAGR) of 8.3%.
Tech ID/UC Case
24323/2014-912-0
Related Cases
2014-912-0
- *Abstract
-
In order to make antibodies, T helper cells need to activate B cells. This activation subsequently leads to the production of antibodies by plasma cells. Thus, deficiencies in T cells impair the immune system and cause devastating diseases like AIDS. A group of UCR scientists lead by Professor David Lo, developed a technology to bypass the need for T helper cells in initiating the immune response also known as T cell independent immunogenicity. They achieved this by coupling a Dengue virus antigen to a core polymeric filament-forming Flagellin. This modified Flagellin acts as both a structure scaffold and adjuvant.
- *IP Issue Date
- Jun 21, 2018
- *Principal Investigator
-
Name: Kaila Bennett
Department:
Name: David Lo
Department:
- Country/Region
- USA
